Live Breaking News & Updates on Fizer Aktie

Stay updated with breaking news from Fizer aktie. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Pfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25

11.04.2024 - Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual-only 2024 Annual Meeting of Shareholders at 9:00 a.m. EDT on Thursday, April 25, 2024. Pfizer has designed the virtual Annual . Seite 1 ....

Pfizer Chart , Fizer Kurs , Fizer Aktie ,

European Commission Approves Pfizer's ELREXFIO for Relapsed and Refractory Multiple Myeloma

08.12.2023 - Pfizer Inc. (NYSE:PFE) today announced the European Commission (EC) has granted conditional marketing authorization for ELREXFIO (elranatamab). ELREFXIO is a targeted immunotherapy for the treatment of adult patients with relapsed and refractory . ....

United Kingdom , Al Hamed , Exchange Commission , Approval Program , Drug Administration , European Commission , National Cancer Institute , Myeloma Research Foundation , World Health Organization , End Results Program , Healthcare Products Regulatory Agency , European Medicines Agency , Committee For Medicinal Products Human Use , Medicinal Products , Human Use , Accelerated Approval Program , Project Orbis , United Kingdom Medicines , Healthcare Products , Regulatory Agency , Medicine Designation , Innovation Passport , Mitigation Strategy , Wallet Card , Prescribing Information , Pfizer Oncology ,

U.S. FDA Approves Pfizer's VELSIPITY for Adults with Moderately to Severely Active Ulcerative Colitis (UC)

13.10.2023 - Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved VELSIPITY (etrasimod), an oral, once-daily, selective sphingosine-1-phosphate (S1P) receptor modulator for adults with moderately to severely . ....

United States , Angela Hwang , Michael Chiorean , Registrational Program , Exchange Commission , Colitis Foundation , Crohn Colitis Foundation , Center At Swedish Medical , European Medicines Agency , Chief Commercial Officer , Global Biopharmaceuticals Business , Swedish Medical Center , Michael Osso , Marketing Authorization Application , Posterior Reversible Encephalopathy Syndrome , Change Patient , Annual Report , Looking Information , Factors That May Affect Future , Prescription Medicines , Accessed December , Ethnic Distribution , Inflammatory Bowel Disease , Ulcerative Colitis , Inflamm Bowel , Disease Activity ,

Pfizer Declares Fourth-Quarter 2023 Dividend

04.10.2023 - Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.41 fourth-quarter 2023 dividend on the company’s common stock, payable December 4, 2023, to holders of the Common Stock of record at the close of business on November . ....

Pfizer News , Pfizer Stock , Pfizer Chart , Fizer Kurs , Fizer Aktie ,

Retrospective Observational Study Assessing Real-World Clinical Impact of Switching or Continuing Eliquis or Rivaroxaban Presented at the European Society of Cardiology (ESC) Congress 2023

25.08.2023 - The Bristol Myers Squibb-Pfizer (BMS NYSE: BMY) – (Pfizer NYSE: PFE) Alliance today presented results from ATHENS, a retrospective real-world data study, at the European Society of Cardiology (ESC) Congress 2023 showing that switching from Eliquis . ....

Bristol Myers Squibb , Narinder Bhalla , Exchange Commission , Pfizer Alliance The , Pfizer Inc , Clinformatics Data Mart , Senior Vice President , Worldwide Medical , Established Brands , Bristol Myers , Hazard Ratio , Confidence Interval , Non Valvular Atrial Fibrillation , Approved Indications , Thrombotic Events , Premature Discontinuation , Epidural Anesthesia , Heart Valves , Hemodynamically Unstable Patients , Require Thrombolysis , Pulmonary Embolectomy , Triple Positive Antiphospholipid Syndrome , Antiplatelet Agents , Bristol Myers Squibb Pfizer , Bristol Myers Squibb Pfizer Alliance , Myers Squibb ,